2022 - Research.com Best Female Scientist Award
1998 - Member of the National Academy of Medicine (NAM)
Carol A. Tamminga spends much of her time researching Psychosis, Neuroscience, Schizophrenia, Internal medicine and Psychiatry. Her Psychosis research is multidisciplinary, incorporating perspectives in Bipolar disorder, Cognition, Pharmacology and Antipsychotic. Her study focuses on the intersection of Neuroscience and fields such as Glutamate receptor with connections in the field of NMDA receptor.
The study incorporates disciplines such as Haloperidol, Anterior cingulate cortex, Anesthesia and Limbic system in addition to Schizophrenia. Carol A. Tamminga works mostly in the field of Internal medicine, limiting it down to concerns involving Endocrinology and, occasionally, Receptor and Cerebrospinal fluid. Carol A. Tamminga has included themes like Clinical Global Impression and Clinical psychology in her Psychiatry study.
Her primary areas of investigation include Psychosis, Neuroscience, Schizophrenia, Internal medicine and Psychiatry. The Schizoaffective disorder research she does as part of her general Psychosis study is frequently linked to other disciplines of science, such as Proband, therefore creating a link between diverse domains of science. Her Neuroscience study frequently draws connections between related disciplines such as NMDA receptor.
Carol A. Tamminga interconnects Anesthesia and Pharmacology in the investigation of issues within Schizophrenia. Her study looks at the intersection of Pharmacology and topics like Haloperidol with Dyskinesia. Her Internal medicine study deals with Endocrinology intersecting with Receptor.
Carol A. Tamminga focuses on Psychosis, Schizophrenia, Neuroscience, Bipolar disorder and Cognition. Psychosis is a subfield of Psychiatry that Carol A. Tamminga investigates. Her study in Schizophrenia is interdisciplinary in nature, drawing from both White matter, Endocrinology, Genome-wide association study and Internal medicine, Disease.
The study incorporates disciplines such as Transcriptome and Gene in addition to Neuroscience. Her Bipolar disorder research incorporates elements of Schizoaffective disorder and Mood. Her Cognition study incorporates themes from Biomarker and Clinical psychology.
Carol A. Tamminga mostly deals with Psychosis, Schizophrenia, Neuroscience, Bipolar disorder and Schizoaffective disorder. She integrates Psychosis and Proband in her research. Her Schizophrenia research integrates issues from Genetics, DNA methylation, Mania, Health equity and Single-nucleotide polymorphism.
Her studies deal with areas such as Transcriptome and Disease as well as Neuroscience. Her Bipolar disorder research entails a greater understanding of Psychiatry. Her Prefrontal cortex study, which is part of a larger body of work in Psychiatry, is frequently linked to Outreach, bridging the gap between disciplines.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Molecular Adaptations Underlying Susceptibility and Resistance to Social Defeat in Brain Reward Regions
Vaishnav Krishnan;Ming Hu Han;Danielle L. Graham;Olivier Berton.
Cell (2007)
Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics
Dean F. Wong;Henry N. Wagner;Larry E. Tune;Robert F. Dannals.
Science (1986)
Subanesthetic doses of ketamine stimulate psychosis in schizophrenia
Adrienne C. Lahti;Bettylou Koffel;David LaPorte;David LaPorte;Carol A. Tamminga.
Neuropsychopharmacology (1995)
Altered Gene Expression of Brain-Derived Neurotrophic Factor and Receptor Tyrosine Kinase B in Postmortem Brain of Suicide Subjects
Yogesh Dwivedi;Hooriyah S. Rizavi;Robert R. Conley;Rosalinda C. Roberts.
Archives of General Psychiatry (2003)
Effects of Ketamine in Normal and Schizophrenic Volunteers
Adrienne C Lahti;Martin A Weiler;B.A Tamara Michaelidis;Arti Parwani.
Neuropsychopharmacology (2001)
Limbic System Abnormalities Identified in Schizophrenia Using Positron Emission Tomography With Fluorodeoxyglucose and Neocortical Alterations With Deficit Syndrome
Carol A. Tamminga;Gunvant K. Thaker;Robert Buchanan;Brian Kirkpatrick.
Archives of General Psychiatry (1992)
Increased cortical kynurenate content in schizophrenia.
Robert Schwarcz;Arash Rassoulpour;Hui Qiu Wu;Deborah Medoff.
Biological Psychiatry (2001)
Neuroleptic withdrawal in schizophrenic patients. A review of the literature.
P L Gilbert;M J Harris;L A McAdams;D V Jeste.
Archives of General Psychiatry (1995)
Antidepressant actions of histone deacetylase inhibitors.
Herbert E. Covington;Ian Maze;Quincey C. LaPlant;Vincent F. Vialou.
The Journal of Neuroscience (2009)
Antidepressant Effect of Optogenetic Stimulation of the Medial Prefrontal Cortex
Herbert E. Covington Iii;Mary Kay Lobo;Ian Maze;Vincent Vialou.
The Journal of Neuroscience (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Yale University
Beth Israel Deaconess Medical Center
University of Cincinnati
University of Georgia
University of Chicago
University of Alabama at Birmingham
University of Alabama at Birmingham
National Institutes of Health
Icahn School of Medicine at Mount Sinai
Northwestern University
University of California, Santa Cruz
University of Latvia
University of Rostock
Indian Institute of Science Education and Research, Bhopal
Stanford University
University of Zaragoza
Chinese University of Hong Kong
University of California, Davis
Martin Luther University Halle-Wittenberg
University of Florida
Celera Corporation
University of Costa Rica
Peking University
Leiden University
The University of Texas at Austin
George Institute for Global Health